Literature DB >> 17669044

Use of basal serum or plasma cortisol concentrations to rule out a diagnosis of hypoadrenocorticism in dogs: 123 cases (2000-2005).

Elizabeth M Lennon1, Tonya E Boyle, Rae Grace Hutchins, Arit Friedenthal, Maria T Correa, Sally A Bissett, Lorra S Moses, Mark G Papich, Adam J Birkenheuer.   

Abstract

OBJECTIVE: To determine whether basal serum or plasma cortisol concentration can be used as a screening test to rule out hypoadrenocorticism in dogs.
DESIGN: Retrospective case-control study. ANIMALS: 110 dogs with nonadrenal gland illnesses and 13 dogs with hypoadrenocorticism. PROCEDURES: Sensitivity and specificity of basal serum or plasma cortisol concentrations of either <or= 1 microg/dL or <or= 2 microg/dL to detect dogs with hypoadrenocorticism were estimated by use of the ACTH stimulation test as the gold standard.
RESULTS: Basal cortisol concentrations of <or= 1 microg/dL had excellent sensitivity (100%) and specificity (98.2%) for detecting dogs with hypoadrenocorticism. For basal cortisol concentrations of <or= 2 microg/dL, sensitivity was 100% but specificity was 78.2%. CONCLUSIONS AND CLINICAL RELEVANCE: On the basis of sensitivity and specificity, basal serum or plasma cortisol concentrations had high negative predictive values over a wide range of prevalence rates and can be used to rule out a diagnosis of hypoadrenocorticism. Dogs with basal cortisol concentrations > 2 microg/dL that are not receiving corticosteroids, mitotane, or ketoconazole are highly unlikely to have hypoadrenocorticism. However, if the basal cortisol concentration is <or= 2 microg/dL, little to no information regarding adrenal gland function can be obtained and an ACTH stimulation test should be performed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669044     DOI: 10.2460/javma.231.3.413

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  18 in total

1.  A retrospective study of dogs with atypical hypoadrenocorticism: a diagnostic cut-off or continuum?

Authors:  J A Wakayama; E Furrow; L K Merkel; P J Armstrong
Journal:  J Small Anim Pract       Date:  2017-03-01       Impact factor: 1.522

2.  Canine hypoadrenocorticism: part II.

Authors:  Susan C Klein; Mark E Peterson
Journal:  Can Vet J       Date:  2010-02       Impact factor: 1.008

3.  Evaluation of the genetic basis of primary hypoadrenocorticism in Standard Poodles using SNP array genotyping and whole-genome sequencing.

Authors:  Steven G Friedenberg; Katharine F Lunn; Kathryn M Meurs
Journal:  Mamm Genome       Date:  2016-11-18       Impact factor: 2.957

4.  Hypoadrenocorticism mimicking protein-losing enteropathy in 4 dogs.

Authors:  Janne G Lyngby; Rance K Sellon
Journal:  Can Vet J       Date:  2016-07       Impact factor: 1.008

5.  A suspected case of Addison's disease in cattle.

Authors:  Bianca Lambacher; Thomas Wittek
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

6.  Prevalence and clinical features of hypoadrenocorticism in Great Pyrenees dogs in a referred population: 11 cases.

Authors:  Magali Decôme; Marie-Claude Blais
Journal:  Can Vet J       Date:  2017-10       Impact factor: 1.008

7.  Basal serum cortisol concentration as a screening test for hypoadrenocorticism in dogs.

Authors:  C Bovens; K Tennant; J Reeve; K F Murphy
Journal:  J Vet Intern Med       Date:  2014-07-28       Impact factor: 3.333

8.  Evaluation of Basal Serum or Plasma Cortisol Concentrations for the Diagnosis of Hypoadrenocorticism in Dogs.

Authors:  A J Gold; D K Langlois; K R Refsal
Journal:  J Vet Intern Med       Date:  2016-10-07       Impact factor: 3.333

9.  Acquired nephrogenic diabetes insipidus in a dog with leptospirosis.

Authors:  Jamie L Etish; Peter S Chapman; Alan R Klag
Journal:  Ir Vet J       Date:  2014-04-17       Impact factor: 2.146

10.  Use of the cortisol-to-ACTH ratio for diagnosis of primary hypoadrenocorticism in dogs.

Authors:  P Lathan; J C Scott-Moncrieff; R W Wills
Journal:  J Vet Intern Med       Date:  2014-06-25       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.